Matthew Del Giudice
Vermögen: 16 000 $ am 30.06.2026
Vermögen: 16 000 $ am 30.06.2026
Matthew Paul Del Giudice is currently an Independent Director at MIRA Pharmaceuticals, Inc. and Telomir Pharmaceuticals, Inc., both positions starting in 2024.
Formerly, the role was Head-General Overnight Emergency Radiologist at The Cleveland Clinic Foundation from 2021 to 2022.
Education includes undergraduate studies at the University of Illinois At Urbana–Champaign and a doctorate from Stritch School of Medicine.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.05.2026 | 12.500 ( 0,04 % ) | 16 000 $ | 30.06.2026 | |
| 12.06.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| MIRA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 13.03.2024 |
| TELOMIR PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 12.08.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
The Cleveland Clinic Foundation
The Cleveland Clinic Foundation Medical/Nursing ServicesHealth Services Provides healthcare services | Corporate Officer/Principal | 01.05.2022 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
The Cleveland Clinic Foundation
The Cleveland Clinic Foundation Medical/Nursing ServicesHealth Services Provides healthcare services | Health Services |
Stritch School of Medicine
Stritch School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois At Urbana–Champaign
University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Develops and sells new molecular synthetic THC for the treatment of adult patients with anxiety and cognitive decline | Health Technology |
Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops a novel small molecule as the first regulator of telomere length and genomic stability | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen